Skip to content

Effect of Vasa Avaleha and its granules on Tamaka Shwasa (Bronchial Asthma)

Pharmaceutical standardization of Vasa Avaleha and its granules with their efficacy on Tamaka Shwasa (Bronchial Asthma)

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2012/12/003184
Enrollment
60
Registered
2012-12-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients suffering from Asthma

Interventions

Intervention1: VasaAvaleha: Dose: 6 gm two times a day with luke- warm water orally in the morning and evening. Duration: Study will be carried out for 28 days (4 weeks). Follow-up: Follow-up study w

Sponsors

Institute for post gradute teaching and research in ayurved
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Both the sexes having age between 12 years to 70 years 2. Mild persistent cases of Asthma (as per WHO GINA Guideline) of duration more than 6 months. 3. Symptoms/exacerbation (Wheeze, cough and breathlessness) greater than weekly and less than daily in frequency. 4. Night symptoms twice per month but less than once a week.

Exclusion criteria

Exclusion criteria: 1. Age more than 70 years and below 12 years. 2. Mild intermittent, Moderated persistent, severe persistent to severe Asthma. 3. Dyspnoea resulting from other diseases like left ventricular failure, COPD (Chronic Bronchitis, Emphysema), upper respiratory tract obstruction, bronchiectasis, cases of tuberculosis, interstitial lung disease/occupational lung disease, tropical pulmonary eosinophilia & allergic bronchopulmonary aspergillosis etc. 4. Patients having anaemia, pneumonia, tuberculosis, lung cancer, lung abscess and other such complicated conditions. 5. Patients having diabetes, hypertension, Chronic and Acute renal failure etc. conditions in which urination is markedly diminished or excessive were excluded. 6. HIV positive cases. 7. Pregnant/lactating mother. 8. Patients who need Salbutamol inhaler daily. 9. Patients having classical symptoms of Maha, Urdha, Chhinna and Kshudra Shwasa.

Design outcomes

Primary

MeasureTime frame
Symptomatic reliefTimepoint: 28days

Secondary

MeasureTime frame
Symptomatic reliefTimepoint: 14days

Countries

India

Contacts

Public ContactProf P K Prajapati

Gujarat Ayurved University

patgiri06@yahoo.co.in09426947438

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026